Dipeptidyl Peptidase 4 Inhibitors Decrease the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Infection and Type 2 Diabetes Mellitus: A Nationwide Study in Taiwan
Introduction: Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors) are incretin-based oral antidiabetic drugs. Previous studies have shown an association between increased plasma activity of DPP-4 and chronic hepatitis C virus (HCV) infection. Dipeptidyl peptidase 4 inhibitors may be associated with...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2021-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_f41e7cd8727e457688acf1ba2a1fe8dc | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Wei-Hao Hsu |e author |
| 700 | 1 | 0 | |a Wei-Hao Hsu |e author |
| 700 | 1 | 0 | |a Shu-Ping Sue |e author |
| 700 | 1 | 0 | |a Shu-Ping Sue |e author |
| 700 | 1 | 0 | |a Hsiu-Ling Liang |e author |
| 700 | 1 | 0 | |a Hsiu-Ling Liang |e author |
| 700 | 1 | 0 | |a Chin-Wei Tseng |e author |
| 700 | 1 | 0 | |a Chin-Wei Tseng |e author |
| 700 | 1 | 0 | |a Hsiu-Chu Lin |e author |
| 700 | 1 | 0 | |a Hsiu-Chu Lin |e author |
| 700 | 1 | 0 | |a Wei-Lun Wen |e author |
| 700 | 1 | 0 | |a Wei-Lun Wen |e author |
| 700 | 1 | 0 | |a Mei-Yueh Lee |e author |
| 700 | 1 | 0 | |a Mei-Yueh Lee |e author |
| 245 | 0 | 0 | |a Dipeptidyl Peptidase 4 Inhibitors Decrease the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Infection and Type 2 Diabetes Mellitus: A Nationwide Study in Taiwan |
| 260 | |b Frontiers Media S.A., |c 2021-09-01T00:00:00Z. | ||
| 500 | |a 2296-2565 | ||
| 500 | |a 10.3389/fpubh.2021.711723 | ||
| 520 | |a Introduction: Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors) are incretin-based oral antidiabetic drugs. Previous studies have shown an association between increased plasma activity of DPP-4 and chronic hepatitis C virus (HCV) infection. Dipeptidyl peptidase 4 inhibitors may be associated with preventing the development of chronic HCV infection. The aim of this study was to investigate whether the use of DPP-4 inhibitors is associated with a decreased risk of hepatocellular carcinoma (HCC) in patients with diabetes mellitus (DM) and chronic HCV infection.Methods: In this retrospective cohort study, we enrolled patients with type 2 diabetes and chronic HCV infection from the National Health Insurance Research Database (NHIRD) in Taiwan. The patients were divided into two groups (DPP-4 inhibitor cohort and non-DPP-4 inhibitor cohort) according to whether or not they received DPP-4 inhibitor treatment.Results: Multivariate Cox proportional hazard regression analysis showed a significantly lower risk of HCC in the patients who took DPP-4 inhibitors compared to those who did not. Kaplan-Meier survival analysis demonstrated a significantly higher HCC-free rate in the DPP-4 inhibitor cohort than in the non-DPP-4 inhibitor cohort.Conclusion: The use of DPP-4 inhibitors was associated with a lower risk of HCC in patients with type 2 DM and chronic HCV infection. | ||
| 546 | |a EN | ||
| 690 | |a dipeptidyl peptidase 4 inhibitors | ||
| 690 | |a diabetes mellitus | ||
| 690 | |a hepatitis C virus infection | ||
| 690 | |a hepatocellular carcinoma | ||
| 690 | |a antidiabetic drugs | ||
| 690 | |a Public aspects of medicine | ||
| 690 | |a RA1-1270 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Frontiers in Public Health, Vol 9 (2021) | |
| 787 | 0 | |n https://www.frontiersin.org/articles/10.3389/fpubh.2021.711723/full | |
| 787 | 0 | |n https://doaj.org/toc/2296-2565 | |
| 856 | 4 | 1 | |u https://doaj.org/article/f41e7cd8727e457688acf1ba2a1fe8dc |z Connect to this object online. |